Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: A systematic review of the evidence

International Journal of Health Services

Volumn 34, Issue 1, 2004, Pages 101-122

  Lexchin, Joel ^a   Grootendorst, Paul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

DRUG USER; FINANCIAL PROVISION; HEALTH SERVICES; HEALTH STATUS;

DRUG COST; DRUG INDUSTRY; DRUG USE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HEALTH SERVICE; HEALTH STATUS; HUMAN; MEDICAID; MEDICARE; PHARMACY; PRESCRIPTION; REVIEW;

CHRONIC DISEASE; DEDUCTIBLES AND COINSURANCE; DRUG UTILIZATION; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH SERVICES; HEALTH STATUS; PHYSICIAN'S PRACTICE PATTERNS; POVERTY; PRESCRIPTION FEES;

EID: 1642280042     PISSN: 00207314     EISSN: None     Source Type: Journal    
DOI: 10.2190/4M3E-L0YF-W1TD-EKG0     Document Type: Review

References (39)

1. Jacobzone, S. Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals. Labour Market and Social Policy Occasional Papers No. 40. Organization for Economic Co-operation and Development, Paris, 2000.
2. Canadian Institute for Health Information. National Health Expenditure Trends, 1975-2002. Ottawa, January 2003.
3. Titlow, K., et al. Drug coverage decisions: The role of dollars and values. Health Aff. 19(2): 240-247, 2000.
4. Grootendorst, P., et al. The impact of reference pricing of nitrates on the use and costs of anti-anginal drugs. CMAJ 165: 1011-1019, 2001.
5. Motheral, B. M., and Fairman, K. A. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med. Care 39: 1293-1304, 2001.
6. Grootendorst, P. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: History and assessment. Can. J. Clin. Pharmacol. 9: 79-99, 2002.
7. Hurley, J., and Arbuthnot-Johnson, N. The effects of copayments within drug reimbursement programs. Can. Public Policy 17: 473-489, 1991.
8. Huttin, C. The use of prescription charges. Health Policy 27(1): 53-73, 1994.
9. Gerdtham, U.-G., and Johanneson, M. The impact of user charges on the consumption of drugs: Empirical evidence and economic implications. Pharmacoeconomics 9: 478-483, 1996.
10. Adams, A. S., Soumerai, S. B., and Ross-Degnan, D. The case of a Medicare drug coverage benefit: A critical review of the empirical evidence. Annu. Rev. Public Health 22: 49-61, 2001.
11. Blais, L., et al. Impact of the Quebec cost sharing drug plan on asthmatic patients receiving social assistance. Can. J. Clin. Pharmacol. 6: 42, 1999.
12. Coulson, N. E., and Stuart, B. C. Insurance choice and the demand for prescription drugs. South. Econ. J. 61: 1146-1157, 1995.
13. Coulson, N. E., et al. Estimating the moral-hazard effect of supplemental medical insurance in the demand for prescription drugs by the elderly. Am. Econ. Rev. 85: 122-126, 1995.
14. Department of Health and Human Services. Report to the President: Prescription Drug Coverage, Spending, Utilization and Prices. Rockville, Md., April 2000. www.aspe.hhs.gov/health/reports/drugstudy (September 8, 2002).
15. Fortess, E. E., et al. Utilization of essential medications by vulnerable older people after a drug benefit cap: Importance of mental disorders, chronic pain, and practice setting. J. Am. Geriatr. Soc. 49: 793-797, 2001.
16. Grootendorst, P. V., O'Brien, B. J., and Anderson, G. M. On becoming 65 in Ontario: Effects of drug plan eligibility on use of prescription medicines. Med. Care 35: 386-398, 1997.
17. Grootendorst, P. V. Health care policy evaluation using longitudinal insurance claims data: An application of the panel Tobit estimator. Health Econ. 6: 365-382, 1997.
18. Kozyrskyj, A. L., et al. Income-based drug benefit policy: Impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. CMAJ 165: 897-902, 2001.
19. Lingle, E. W. Jr., Kirk, K. W., and Kelly, W. R. The impact of outpatient drug benefits on the use and costs of health care services for the elderly. Inquiry 24: 203-211, 1987.
20. Martin, B. C., and McMillan, J. A. The impact of implementing a more restrictive prescription limit on Medicaid recipients: Effects on cost, therapy, and out-of-pocket expenditures. Med. Care 34: 686-701, 1996.
21. Nelson, A. A. Jr., Reeder, C. E., and Dickson, W. M. The effect of a Medicaid drug copayment program on the utilization and cost of prescription services. Med. Care 22: 724-736, 1984.
22. Poisal, J. A., and Chulis, G. S. Medicare beneficiaries and drug coverage. Health Aff. 19(2): 248-256, 2000.
23. Reeder, C. E., and Nelson, A. A. The differential impact of copayment on drug use in a Medicaid population. Inquiry 22: 396-403, 1985.
24. Scott, D. M., Nordin, J. D., and Lally, J. M. Medication fees and their impact on prescribing habits for the near-poor. J. Pharmacoepidemiol. 1(1): 23-33, 1990.
25. Shih, Y. C. Effect of insurance on prescription drug use by ESRD beneficiaries. Health Care Financ. Rev. 20(3): 39-54, 1999.
26. Soumerai, S. B., et al. Payment restrictions for prescription drugs under Medicaid: Effects on therapy, cost, and equity. N. Engl. J. Med. 317: 550-556, 1987.
27. Soumerai, S. B., et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N. Engl. J. Med. 325: 1072-1077, 1991.
28. Soumerai, S. B., et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N. Engl. J. Med. 331: 650-655, 1994.
29. Steinman, M. A., Sands, L. P., and Covinsky, K. E. Self-restriction of medications due to cost in seniors without prescription coverage: A national survey. J. Gen. Intern. Med. 16: 793-799, 2001.
30. Stuart, B., Shea, D., and Briesacher, B. Prescription Drug Costs for Medicare Beneficiaries: Coverage and Health Status Matter. Commonwealth Fund, New York, 2000. www.cmwf.org/programs/medfutur/stuart_drug_ib_365.asp (September 8, 2002).
31. Stuart, B., and Zacker, C. Who bears the burden of Medicaid drug copayment policies? Health Aff. 18(2):201-212, 1999.
32. Tamblyn, R., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285: 421-429, 2001.
33. Van Doorslaer, E. The effects of cost sharing on the demand for prescription drugs in Belgium. Acta Hospitalia 3: 69-81, 1984.
34. Watt, J., et al. The effect of the increased prescription charges on the collection of asthma drugs. N.Z. Med. J. 105: 153-154, 1992.
35. Schulz, R. M., et al. Drug use behavior under the constraints of a Medicaid prescription cap. Clin. Ther. 17: 330-340, 1995.
36. Smith, D. G., and Kirking, D. M. Impact of consumer fees on drug utilization. Pharmacoeconomics 2: 335-342, 1992.
37. Motheral, B. R., and Henderson, R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am. J. Manage. Care 5: 1383-1394, 1999.
38. Besley, T., and Case, A. Unnatural experiments? Estimating the incidence of endogenous policies. Econ. J. 11: F672-F694, 2000.
39. Soumerai, S. B., et al. Determinants of change in Medicaid pharmaceutical cost sharing: Does evidence affect policy? Milbank Q. 75: 11-34, 1997.